TCBP TC BioPharm (Holdings) Plc: Forward Price-to-Revenue Multiple
The forward P/S ratio allows for an assessment of the asset's value dynamics, with 0.20 serving as the current value of the indicator. TC Biopharm revenues will be based on the implementation of gamma-delta T-cell therapy against leukemia. The company's innovative approach simplifies the mass application of cancer immunotherapy. The stability of R&D processes is guaranteed through a system of grants and the retention of key immunologists.
TC BioPharm Ltd (TCBP) - metric breakdowns and financial figures
- current price and projected stock value:
- company stock capitalization data:
- business book valuation details:
- debt obligations and liquidity statistics:
- financial results and valuation multiples details:
TCBP - Final Profit|Projected Future Earnings TC Biopharm|TCBP - P/E Multiple|Future Price to Earnings TC BioPharm (Holdings) PLC|TCBP - Growth-Adjusted Payback Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization TC Biopharm|TCBP - Operating profit before deduction of amortization|Net earnings per share for the last 12 months TC BioPharm|TCBP - Earnings per share for the last four quarters|Quarterly EPS earnings growth tcbiopharm.com|TCBP - Net earnings per share growth this year|Earnings growth forecast for next year TC Biopharm
- sales and revenue data:
Comprehensive company analysis:TCBP (TC BioPharm)
Forward P/S measures the market value of TC Biopharm relative to expected sales volume, allowing for an assessment of investor confidence in management's long-term strategy during the intervals between earnings reports. The trend of this forward revenue multiple reflects the speculative premium on TC Biopharm capital, which depends directly on the commercialization prospects of its available allogeneic gamma-delta T-cell based cancer therapy.
Competitor analysis
Forward P/S Multiple ARGX (argenx)|BioNTech Inc. (BNTX) - Market Cap to Future Revenue Ratio|ABVX: Forward Price-to-Revenue Multiple|ADMA Corp - Price to Expected Revenue Ratio|PTGX: Forward P/S Multiple|Forward Price-to-Revenue Multiple immunovant.com|Forward Price-to-Revenue Multiple KNSA|GRFS: Forward Price to Sales|Forward P/S Multiple ADPT|Price-to-Projected Revenue Ratio CLDX (Celldex Corp)|Forward P/S Multiple AUPH (Aurinia Pharmaceuticals)|Market Cap to Expected Sales Ratio biocryst.com (BCRX)|VERA - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Dianthus Therapeutics Inc|Pharvaris Corp (PHVS) - Price-to-Projected Revenue Ratio|Future Price to Revenue ABCL (AbCellera Corp)|TRML (Tourmaline Bio, Inc.) - Forward P/S Multiple|PGEN: Forward Price to Sales|Forward P/S Multiple PHAR|Forward P/S Multiple Nektar Therapeutics Inc (NKTR)|Price-to-Projected Revenue Ratio Upstream Bio Corp UPB|Forward Price to Sales ZBIO|IMNM - Price-to-Projected Revenue Ratio|gossamerbio.com (GOSS) - Forward Price-to-Revenue Multiple|KALV (KalVista Pharmaceuticals, Inc.) - Forward Price-to-Revenue Multiple|SEPN: Price to Expected Revenue Ratio|PVLA (Pieris Pharmaceuticals Inc) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Savara Pharma (SVRA)|Forward P/S Multiple RIGL|Price-to-Projected Revenue Ratio ANAB (anaptysbio.com)|Price-to-Projected Revenue Ratio Astria Therapeutics, Inc. ATXS|ENGN (enGene Holdings Inc) - Future Price to Revenue|RAPT - Price-to-Projected Revenue Ratio|Future Price to Revenue JBIO|ACRS: Forward P/S Multiple|kyvernatx.com - Forward Price to Sales|TLSA (Tiziana Life Sciences Ltd) - Forward P/S Multiple|Forward P/S Multiple Cabaletta Bio Inc.|Price-to-Projected Revenue Ratio Ventyx Bio (VTYX)|THTX (Theratechnologies, Inc) - Forward Price to Sales|Price-to-Projected Revenue Ratio Avalo Therapeutics, Inc AVTX|ELDN - Forward Price-to-Revenue Multiple|Agenus Inc. - Forward P/S Multiple|CLYM - Forward P/S Multiple|ZURA (Zura Bio Limited) - Forward Price-to-Revenue Multiple|aTyr Pharmaceuticals - Forward Price to Sales|ADAG (Adagene Inc) - Forward P/S Multiple|Ikena Oncology, Inc. (IMA) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Shattuck Labs, Inc. (STTK)|Forward Price-to-Revenue Multiple equilliumbio.com EQ|Price-to-Projected Revenue Ratio Connect Biopharma Holdings Limited CNTB|IMUX - Forward Price-to-Revenue Multiple|ATRA: Forward Price-to-Revenue Multiple|IFRX - Forward P/S Multiple|X4 Pharmaceuticals, Inc. (XFOR) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue ACET|CELU (Celularity Inc) - Forward P/S Multiple|Market Cap to Future Revenue Ratio INmune Bio Corporation INMB|Forward Price-to-Revenue Multiple BRNS (Barinthus Biotherapeutics)|Price to Expected Revenue Ratio KZR|Forward P/S Multiple SABS (SAB Biotherapeutics, Inc.)|AKTX - Forward Price-to-Revenue Multiple|ENLV: Forward Price-to-Revenue Multiple|Forward Price to Sales QTTB (Q32 Bio Inc.)|GOVX: Forward P/S Multiple|EDSA (edesabiotech.com) - Price-to-Projected Revenue Ratio|IBIO (iBio) - Forward P/S Multiple|Carisma Tx (CARM) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio XTL Biopharmaceuticals, Ltd. (XTLB)|BOLT - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio HCW Biologics HCWB|APVO (Aptevo Therapeutics, Inc.) - Future Price to Revenue|AIM ImmunoTech - Forward P/S Multiple|Forward Price to Sales ADTX (Aditxt)|GRI: Forward P/S Multiple|XORTX Corp (XRTX) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Vyome Holdings Inc|REVB: Forward Price to Sales|Price-to-Projected Revenue Ratio Indaptus Therapeutics, Inc. (INDP)|Forward Price-to-Revenue Multiple Scinai Immunotherapeutics Ltd SCNI|CalciMedica - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio AFMD (Affimed NV)|Allakos Therapeutics - Forward P/S Multiple|HOOKIPA Pharma Inc. (HOOK) - Forward Price-to-Revenue Multiple|IGMS: Forward P/S Multiple|ITOS (iTeos Therapeutics Inc) - Price-to-Projected Revenue Ratio|Price-to-Projected Revenue Ratio Ocean Bio|Third Harmonic Bio Inc - Future Price to Revenue
